loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Cyproterone Acetate

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Cyproterone Acetate

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,818Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EMA committee recommends restriction in use of cyproterone
    EMA committee recommends restriction in use of cyproterone

    31 Mar 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=122067&sid=2

    PHARMABIZ
    31 Mar 2020
    Share Share
    Restrictions in use of cyproterone due to meningioma risk
    Restrictions in use of cyproterone due to meningioma risk

    28 Mar 2020

    // EMA

    https://www.ema.europa.eu/en/news/restrictions-use-cyproterone-due-meningioma-risk-0

    EMA
    28 Mar 2020
    Share Share
    Restrictions in use of cyproterone due to meningioma risk
    Restrictions in use of cyproterone due to meningioma risk

    14 Feb 2020

    // EMA

    https://www.ema.europa.eu/en/news/restrictions-use-cyproterone-due-meningioma-risk

    EMA
    14 Feb 2020
    Share Share